CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 10 target
Drug / intervention
Semaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07282769
NCT07282769Phase 2Not Yet Recruiting
CompareCT.gov

Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study

University of Chicago·interventional·Posted Dec 15, 2025·Updated Jun 10, 2026

In Brief

A Phase 2 clinical trial evaluating Semaglutide for Trichotillomania (Hair-Pulling Disorder) and 4 related conditions. Not yet recruiting, targeting 10 participants.

Detailed Summary

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder
Countries--
Collaborators--

Timeline

Phase 2Not Yet Recruiting
20262027
First PostedDec 15, 2025
Enrollment StartJun 1, 2026
Primary CompletionFeb 1, 2027
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 7 months agoPrimary completion in 7 months

Interventions

Semaglutidedrug

All participants in the study will receive semaglutide (Wegovy).